Reference health
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study
00333-7/badge.svg){kind=icon}
23/23 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
6 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 23 checked references that resolve
resolves10.1136/gutjnl-2020-322539
Effect of IBD medications on COVID-19 outcomes: results from an international registry
resolves10.1016/j.jaci.2020.10.007
Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study
resolves10.1136/annrheumdis-2020-219498
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
resolves10.1016/S0140-6736(21)00947-8
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
resolves10.1136/annrheumdis-2021-220272
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
resolves10.7326/M21-1451
Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series
resolves10.7326/M21-1757
Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2
resolves10.1053/j.gastro.2021.04.025
Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies
resolves10.1016/S0140-6736(21)00432-3
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
resolves10.1016/S2665-9913(21)00212-5
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study
resolves10.1136/gutjnl-2021-324789
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
resolves10.1016/S0140-6736(21)01358-1
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness
resolves10.1038/s41564-020-00813-8
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
resolves10.1136/annrheumdis-2021-220597
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
resolves10.1016/j.immuni.2021.08.001
Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination
resolves10.1038/s41586-021-03738-2
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses
resolves10.1016/j.lanepe.2021.100208
Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study
resolves10.1136/annrheumdis-2018-213222
Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial
resolves10.1016/S0140-6736(21)01290-3
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
resolves10.1038/s41586-021-03739-1
Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
resolves10.1038/s41564-021-00947-3
Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom
The 6 references without a DOI — listed, not checked
no DOI — not checkedRisk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies: a nationwide cohort study in the OpenSAFELY platform
no DOI — not checkedImpact of vaccination on SARS-CoV-2 cases in the community: a population-based study using the UK's COVID-19 Infection Survey
no DOI — not checkedExtended interval BNT162b2 vaccination enhances peak antibody generation in older people
no DOI — not checked10.1016/S2665-9913(21)00333-7_bib14
no DOI — not checkedREACT-1 round 13 final report: exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant in England during May to July 2021
no DOI — not checkedAntibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/s2665-9913(21)00333-7"><img src="https://citestamp.com/citestamped/10.1016/s2665-9913(21)00333-7/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[00333-7/badge.svg)](https://citestamp.com/citestamped/10.1016/s2665-9913(21)00333-7)